US2010203498A1PendingUtilityA1

Methods and compositions for identifying anti-hcv agents

Assignee: UNIV LELAND STANFORD JUNIORPriority: Aug 22, 2003Filed: Jul 27, 2009Published: Aug 12, 2010
Est. expiryAug 22, 2023(expired)· nominal 20-yr term from priority
G01N 2333/18C12Q 1/707G01N 2500/04G01N 33/5767G01N 33/6875G01N 33/56983
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides methods and compositions for identifying agents for treating infection by viruses that encode a nucleotide-binding NS4B protein, or functional equivalent thereof, e.g., hepatitis C virus (HCV) or other members of the family Flaviviridae. In general, the methods involve contacting an NS4B nucleotide binding motif (NBM)-containing polypeptide with a candidate agent, and determining the effect of the candidate agent on nucleotide binding activity, a nucleotide hydrolyzing activity, or a nucleotide-dependent RNA binding activity of the polypeptide. A candidate agent that inhibits NS4B polypeptide binding to a nucleotide is an anti-viral agent, e.g., an anti-HCV agent. The invention also features a polynucleotide encoding a NS4B polypeptide having a modified NBM (e.g., which is impaired in NTP binding). The subject methods and compositions find use in a variety of therapeutic and screening applications.

Claims

exact text as granted — not AI-modified
1 - 21 . (canceled) 
     
     
         22 . A method comprising:
 contacting a hepatitis C virus (HCV) NS4B protein with a candidate agent and HCV RNA; and   determining an effect of said candidate agent on:
 (i) GTPase activity or nucleotide binding of said NS4B protein; or 
 (ii) HCV RNA binding of said NS4B protein. 
   
     
     
         23 . The method of  claim 22 , wherein said candidate agent is a nucleotide analog. 
     
     
         24 . The method of  claim 23 , wherein said nucleotide analog is a non-hydrolysable nucleotide. 
     
     
         25 . The method of  claim 22 , wherein said method further comprises determining an effect of said candidate agent on HCV replication. 
     
     
         26 . The method of  claim 25 , wherein said method comprises assaying said candidate agent on HCV replication in a liver cell line or primary liver cell.

Join the waitlist — get patent alerts

Track US2010203498A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.